-
公开(公告)号：US09988440B2
公开(公告)日：2018-06-05
申请号：US14309330
申请日：2014-06-19
Applicant: NOVARTIS AG
Inventor： Leslie Ngozi Anuna Johnson , Ute Jaeger , Yong-In Kim , Christian Carsten Silvester Kunz , Igor Splawski , Michael Roguska , Joy Ghosh , Barbara Brannetti , Michael Stefanidakis , Sha-Mei Liao
IPC: A61K39/395 , C07K16/18 , G01N33/68 , C07K16/24 , A61K39/00
CPC classification number: C07K16/18 , A61K39/3955 , A61K2039/505 , A61K2039/507 , C07K16/24 , C07K2317/21 , C07K2317/30 , C07K2317/33 , C07K2317/40 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/92 , G01N33/6863
Abstract: The present invention relates to antibodies or antigen binding fragments thereof that bind to complement Factor P and used thereof as well as combinations of anti-Factor P antibodies with antibodies or antigen binding fragments thereof that bind to complement component 5 (C5).
-
公开(公告)号：US10537648B2
公开(公告)日：2020-01-21
申请号：US15321025
申请日：2015-06-24
Applicant: NOVARTIS AG
Inventor： Joy Ghosh , Thaddeus Peter Dryja , Michael Roguska , Eric C. Carlson
Abstract: The invention provides compositions for rendering a vitreous cavity visible during a surgical procedure to alleviate a structural disorder caused by the vitreous in an eye, and methods of using the compositions. The compositions are vitreous delineating agents that comprise a hyaluronan binding peptide linked to an optically detectable moiety. Such compositions can be in a formulation that may be a solution, a suspension, or an emulsion, and would be injected into the vitreous shortly prior to use. The composition may additionally contain a therapeutic agent, a diagnostic agent, or a chemosensing material, in use, the composition marks or delineates the vitreous by binding preferentially to the hyaluronan that permeates the vitreous humor and binding little or not at all to surrounding tissues such as the retina. The interface between the labelled vitreous humor and the non-labelled surrounding vital tissues produces a visible signal, thereby allowing a surgeon to clearly visualize the entire vitreous cavity and distinguish it from vital ocular structures. Use of the method improves the accuracy and safety of a vitrectomy and thus prevents suboptimal outcomes or the need for repeated procedures. The compositions comprising chemosensing material are useful as long-lasting biosensors, which when used in the vitreous enable repetitive, non-invasive, in vivo measurements of metabolites or pharmacologic agents in the vitreous of animals or humans.
-
Patent Agency Ranking
公开(公告)号：US10106605B2
公开(公告)日：2018-10-23
申请号：US15180879
申请日：2016-06-13
Applicant: Novartis AG
Inventor： Joy Ghosh , Mark Anthony Rutz , Kathrin Ulrike Tissot-Daguette , Igor Splawski , Michael Roguska
Abstract: The present invention relates to compositions and methods for the inhibition of EPO. The invention provides antibodies and antigen binding fragments thereof that bind to EPO and are able to inhibit EPO-dependent cell proliferation and/or EPO-dependent cell signaling.
-
公开(公告)号：US10385127B2
公开(公告)日：2019-08-20
申请号：US16130166
申请日：2018-09-13
Applicant: NOVARTIS AG
Inventor： Joy Ghosh , Mark Anthony Rutz , Kathrin Ulrike Tissot-Daguette , Igor Splawski , Michael Roguska
Abstract: The present invention relates to compositions and methods for the inhibition of EPO. The invention provides antibodies and antigen binding fragments thereof that bind to EPO and are able to inhibit EPO-dependent cell proliferation and/or EPO-dependent cell signaling.
-
公开(公告)号：US09051365B2
公开(公告)日：2015-06-09
申请号：US13716526
申请日：2012-12-17
Applicant: NOVARTIS AG
Inventor： Leslie Ngozi Anuna Johnson , Ute Jaeger , Yong-In Kim , Christian Carsten Silvester Kunz , Igor Splawski , Michael Roguska , Joy Ghosh , Barbara Brannetti , Sha-Mei Liao , Michael Stefanidakis
CPC classification number: C07K16/18 , A61K39/3955 , A61K2039/505 , A61K2039/507 , C07K16/24 , C07K2317/21 , C07K2317/30 , C07K2317/33 , C07K2317/40 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/92 , G01N33/6863
Abstract: The present invention relates to antibodies or antigen binding fragments thereof that bind to complement Factor P and used thereof as well as combinations of anti-Factor P antibodies with antibodies or antigen binding fragments thereof that bind to complement component 5 (C5).
Abstract translation: 本发明涉及结合补体因子P并用于其的抗体或其抗原结合片段，以及抗因子P抗体与结合补体成分5（C5）的抗体或其抗原结合片段的组合。
-
公开(公告)号：US11725246B2
公开(公告)日：2023-08-15
申请号：US16998830
申请日：2020-08-20
Applicant: NOVARTIS AG
Inventor： Joy Ghosh , Yunsheng He
IPC: C12Q1/6883 , A61P27/02 , C07K16/22
CPC classification number: C12Q1/6883 , A61P27/02 , C07K16/22 , C07K2317/24 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C12Q2600/106 , C12Q2600/156
Abstract: The invention features methods of identifying patients as being likely to respond to anti-VEGF therapy. Furthermore, in those patients identified as failing to include one or more of the above ophthalmic response markers, the invention features treatment with an EPO antagonist (e.g., alone, or in combination with a VEGF antagonist).
-
公开(公告)号：US20130295102A1
公开(公告)日：2013-11-07
申请号：US13716526
申请日：2012-12-17
Applicant: Novartis AG
Inventor： Leslie Ngozi Anuna Johnson , Ute Jaeger , Yong-In Kim , Christian Carsten Silvester Kunz , Igor Splawski , Michael Roguska , Joy Ghosh , Barbara Brannetti
IPC: C07K16/18 , G01N33/68 , C07K16/24 , A61K39/395
CPC classification number: C07K16/18 , A61K39/3955 , A61K2039/505 , A61K2039/507 , C07K16/24 , C07K2317/21 , C07K2317/30 , C07K2317/33 , C07K2317/40 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/92 , G01N33/6863
Abstract: The present invention relates to antibodies or antigen binding fragments thereof that bind to complement Factor P and used thereof as well as combinations of anti-Factor P antibodies with antibodies or antigen binding fragments thereof that bind to complement component 5 (C5).
-
-
-
-
-
-
Search Results
7
records
(took 0.042 seconds)
